Contract Duration at the Pleading Stage: “In Effect” Covenants Survive Patent Expiration Unless Expiration Is Compelled as a Matter of Law

Case: Teva Pharmaceuticals USA, Inc. v. Eli Lilly and Company (7th Cir. July 13, 2026)
Panel: Hamilton, Jackson-Akiwumi, and Kolar, Circuit Judges (opinion by Hamilton, J.)
Law Applied: Federal pleading standards (Rule 12(b)(6)); Indiana contract law (duration/interpretation)

1. Introduction

This appeal arises from a breakdown in a Hatch-Waxman settlement between a generic manufacturer (Teva Pharmaceuticals USA, Inc.) and a brand-name manufacturer (Eli Lilly and Company) concerning Lilly’s osteoporosis drug Forteo. After Lilly sued Teva for patent infringement in 2016 following Teva’s FDA filing to market a generic product, the parties settled in January 2018.

Teva later alleged that Lilly violated key settlement covenants—particularly promises not to “prevent or delay” Teva’s approval/launch/manufacture and to “waive any regulatory … exclusivities necessary to effectuate the license as of the Entry Date.” Teva claimed Lilly obtained three years of additional FDA regulatory exclusivity through a labeling-related supplement, which delayed Teva’s final approval until that exclusivity expired in November 2023.

The central issue on appeal was narrow but consequential: whether Teva plausibly alleged breach of contractual obligations that were still “in effect,” even though the settlement agreement did not include a stated termination date and the relevant patents expired in August 2019. The district court dismissed, reasoning the settlement could not extend past patent expiration. The Seventh Circuit reversed.

2. Summary of the Opinion

The Seventh Circuit held that dismissal was improper because Teva plausibly alleged breaches of covenants that could still have been “in effect” when the alleged interference occurred (beginning in January 2020). Where a contract is silent on duration, Indiana law supplies a “reasonable time” term, and reasonableness is typically factual. The court also clarified that, at the pleading stage, Teva was not required to allege a precise termination date for the agreement (or for specific covenants) to survive a Rule 12(b)(6) motion. The panel reversed and remanded for further proceedings.

3. Analysis

3.1. Precedents Cited

A. Rule 12(b)(6) and plausibility pleading

  • Ratfield v. U.S. Drug Testing Laboratories, Inc., 140 F.4th 849 (7th Cir. 2025): Reaffirmed de novo review of pleadings dismissals and the requirement that courts accept well-pleaded facts and reasonable inferences for the plaintiff. The court used Ratfield to frame the lens through which the settlement agreement and alleged breaches must be evaluated.
  • Flores v. City of South Bend, 997 F.3d 725 (7th Cir. 2021), quoting Ashcroft v. Iqbal, 556 U.S. 662 (2009): Supplied the “plausible on its face” standard. The panel treated the agreement’s silence on “in effect” duration as creating a plausible inference in Teva’s favor rather than a pleading defect.
  • Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) and Ashcroft v. Iqbal, 556 U.S. 662 (2009): The court invoked these cases to reject the district court’s approach that effectively required Teva to prove (or pin down) the contract’s end date before discovery.
  • Marcure v. Lynn, 992 F.3d 625 (7th Cir. 2021); Gunn v. Continental Casualty Co., 968 F.3d 802 (7th Cir. 2020); Brockett v. Effingham County, 116 F.4th 680 (7th Cir. 2024): These cases anchored a key procedural point: the defendant bears the burden on a motion to dismiss to show entitlement to dismissal. The panel used them to characterize Lilly’s argument as demanding more than plausibility and improperly shifting burdens.
  • Swanson v. Citibank, N.A., 614 F.3d 400 (7th Cir. 2010); Arnett v. Webster, 658 F.3d 742 (7th Cir. 2011): Swanson’s “story that holds together” formulation and Arnett’s reminder that a complaint may proceed despite doubts about ultimate proof reinforced the panel’s refusal to require a calendar-date termination allegation.

B. Indiana contract duration when a contract is silent

  • City of East Chicago v. East Chicago Second Century, Inc., 908 N.E.2d 611 (Ind. 2009), citing House of Crane Inc. v. H. Fendrich, Inc., 146 Ind. App. 478, 256 N.E.2d 578 (1970): Provided the central Indiana rule that a contract lacking a duration term is effective for a “reasonable time.” This was the doctrinal foundation for rejecting Lilly’s claim that expiration was necessarily coextensive with patent expiration.
  • Rogier v. American Testing & Engineering Corp., 734 N.E.2d 606 (Ind. App. 2000): Explained that “reasonable time” is usually a question of fact informed by the subject matter, party situation, and performance circumstances. The panel relied on Rogier to hold the “in effect” duration question unsuitable for resolution on the pleadings.
  • Restatement (Second) of Contracts § 204 (1981): Cited for the court-supplied “reasonable in the circumstances” term when an essential term is omitted. The panel used the Restatement to emphasize that supplying an omitted term is not simply “contract interpretation” resolvable from text alone.
  • CNH Industrial N.V. v. Reese, 583 U.S. 133 (2018): While arising in a different context, it was cited for applying ordinary contract principles; it supported the court’s broader point that silence does not license courts to insert preferred end dates at the pleading stage.

C. Contract interpretation and “different language, different meaning”

  • USA Gymnastics v. Liberty Insurance Underwriters, Inc., 27 F.4th 499 (7th Cir. 2022); Collins v. University of Notre Dame Du Lac, 929 F.3d 830 (7th Cir. 2019); Right Field Rooftops, LLC v. Chicago Cubs Baseball Club, LLC, 870 F.3d 682 (7th Cir. 2017); Taracorp, Inc. v. NL Industries, Inc., 73 F.3d 738 (7th Cir. 1996): The panel used these cases to apply a textual inference: where the settlement expressly pegged the license “through the expiration” of patents (Section 4.1), but did not similarly peg the Section 5.2 covenants, it was plausible the parties meant different durations.
  • Care Group Heart Hospital, LLC v. Sawyer, 93 N.E.3d 745 (Ind. 2018) and AXIS Insurance Co. v. American Specialty Insurance & Risk Services, 111 F.4th 825 (7th Cir. 2024): Supported the caution against adding tacit terms and “picking up the pen” for the parties—an admonition the panel used to criticize the district court’s effective insertion of a patent-expiration termination date.

D. Waiver/preservation on appeal

  • Yee v. City of Escondido, 503 U.S. 519 (1992) and Lawson v. Sun Microsystems, Inc., 791 F.3d 754 (7th Cir. 2015): The court relied on these to reject Lilly’s “waiver” argument. Teva could advance additional legal support on appeal (e.g., “reasonable time” doctrine) for a properly preserved breach-of-contract claim.

E. Survival of provisions and covenants not to sue

  • Morgan Drive Away, Inc. v. Int'l Brotherhood of Teamsters, Chauffeurs, Warehousemen & Helpers of America, 166 F. Supp. 885 (S.D. Ind. 1958), aff'd, 268 F.2d 871 (7th Cir. 1959): The district court cited it for a presumption against perpetual contracts. The Seventh Circuit did not deny that concern, but treated it as not dispositive at the pleading stage and not a license to impose a patent-expiration endpoint as a matter of law.
  • Tax Track Systems Corp. v. New Investor World, Inc., 478 F.3d 783 (7th Cir. 2007); Chesterfield Management, Inc. v. Cook, 655 N.E.2d 98 (Ind. App. 1995), quoting State ex rel. Ranger Fuel Corp. v. Lilly, 165 W. Va. 98, 267 S.E.2d 435 (1980); Lighting Products Ltd. v. Robertson Transformer Co., No. 13 C 9185, 2015 WL 719521 (N.D. Ill. Feb. 17, 2015): These were discussed in connection with whether certain clauses can survive termination. The panel distinguished them as dealing largely with confidentiality/arbitration clauses and found them unhelpful to Lilly’s attempt to treat substantive covenants as necessarily expiring with patents.
  • Teva Pharmaceuticals USA, Inc. v. Abbott Laboratories, 580 F. Supp. 2d 345 (D. Del. 2008): Used to illustrate that antitrust or similar claims can be brought after patent expiration (subject to limitations). This supported the panel’s point that Teva’s covenant not to sue plausibly continued beyond patent expiration—suggesting the agreement remained “in effect” in a meaningful way.
  • Allied Structural Steel Co. v. Spannaus, 438 U.S. 234 (1978): Cited for the reliance function of contracts; the court used it to rebut Lilly’s suggestion that post-expiration suits would be meritless anyway, emphasizing that parties bargain to avoid being sued, not merely to win later.

F. Hatch-Waxman background (context, not the holding)

  • FTC v. Actavis, Inc., 570 U.S. 136 (2013); Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, 566 U.S. 399 (2012); Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., 608 U.S. —, 146 S. Ct. 1391 (2026): These cases framed the regulatory/patent-litigation environment and incentives (e.g., paragraph IV litigation and 180-day exclusivity), helping explain why settlement provisions about regulatory exclusivities and non-interference can matter even when patents are near expiry.

3.2. Legal Reasoning

A. The core interpretive move: “In effect” ≠ “until patent expiration” as a matter of law

The settlement tied some provisions explicitly to patent expiration (notably, Section 4.1’s license “through the expiration of the [Forteo patents]”). But Section 5.2’s covenants (including non-interference and regulatory-waiver promises) were framed to apply while the agreement was “in effect,” without defining that phrase or stating an end date.

From that drafting choice, the court drew two key conclusions:

  • It is plausible the parties intended different durations for different obligations, because they used different language for parallel timing issues (USA Gymnastics v. Liberty Insurance Underwriters, Inc. and related cases).
  • Indiana law supplies a missing duration term as a “reasonable time,” and whether the agreement (or particular covenants) remained “in effect” into 2020–2023 is typically a fact question (City of East Chicago v. East Chicago Second Century, Inc.; Rogier v. American Testing & Engineering Corp.; Restatement (Second) of Contracts § 204).

B. The “covenant not to sue” as an internal consistency check

The panel stressed that Teva undertook broad, forward-looking restrictions—covenants not to sue and not to challenge—that would make little sense if they evaporated automatically upon patent expiration. If those negative promises plausibly continued after August 2019, then it is likewise plausible that the agreement was still “in effect,” undermining the district court’s categorical cutoff.

C. Rejecting Lilly’s “primary vs. ancillary” distinction

Lilly argued some provisions could survive as “ancillary” (e.g., dispute resolution), while “primary” patent-related obligations should expire with the patents. The court found no textual anchor for that dichotomy and further noted that the covenants at issue—non-interference and regulatory-waiver promises—were central to the settlement’s bargain, not mere “ancillaries.”

D. Pleading doctrine: Teva need not plead a specific termination date

The court’s most practice-shaping reasoning concerns Rule 12(b)(6). It held the district court misapplied pleading standards by demanding Teva identify “an exact date” the agreement ended and treating Teva’s inability to do so as fatal. At this stage, the question is plausibility, and the burden rests on the movant to show dismissal is warranted (Marcure v. Lynn; Gunn v. Continental Casualty Co.; Brockett v. Effingham County). Where “reasonable time” is the governing default and is fact-intensive, insisting on a pleaded termination date improperly front-loads proof and forecloses discovery.

3.3. Impact

A. Contract pleading in duration-silent agreements

The decision strengthens a plaintiff-friendly (but doctrinally orthodox) rule: when a contract’s duration is omitted and state law supplies a “reasonable time,” a complaint can survive without specifying a precise termination date—especially where the defendant’s “it necessarily ended by X date” theory depends on factual reasonableness determinations.

B. Settlement agreements in Hatch-Waxman litigation

Practically, the opinion warns brand and generic parties that post-patent-expiration behavior can still be policed by settlement covenants, particularly those aimed at clearing regulatory obstacles (e.g., waiving exclusivities and not delaying approval). Drafters can expect increased attention to explicit survival/termination clauses for regulatory-cooperation obligations, not merely for licenses tied to patent life.

C. Litigation behavior and motion-to-dismiss strategy

Defendants seeking early dismissal on “contract expired” theories face a higher hurdle where the contract is silent and the proposed end date is not compelled by text. Plaintiffs, conversely, can plead continued effectiveness by tying alleged breaches to ongoing obligations and pointing to contract structure (different timing language in different sections) without prematurely committing to a single end date.

4. Complex Concepts Simplified

  • Hatch-Waxman / Paragraph IV certification: A generic company can seek FDA approval by claiming the brand’s patents are invalid or not infringed. That filing is treated as an “act of infringement,” allowing the brand to sue.
  • 180-day exclusivity: The first generic challenger may receive a 180-day period where other generics are kept out, creating strong incentives to challenge patents.
  • Regulatory exclusivity (distinct from patents): FDA rules can provide market protection independent of patents (e.g., for certain approved changes). A contract may require a brand company to waive or not invoke such exclusivities as to the settling generic.
  • Contract “in effect” when no end date is stated: Many states (including Indiana) treat the contract as lasting a “reasonable time.” What is “reasonable” depends on context and often cannot be decided on the pleadings.
  • Rule 12(b)(6) burden: The defendant must show that even if the complaint’s facts are true, the law still requires dismissal. A plaintiff is not required to prove its case—or resolve fact-heavy questions—before discovery.

5. Conclusion

Teva Pharmaceuticals USA, Inc. v. Eli Lilly and Company establishes a practical pleading rule for duration-silent contracts governed by Indiana’s “reasonable time” default: a plaintiff need not plead a precise termination date to plausibly allege breach of covenants that may still be “in effect.” The Seventh Circuit’s reversal underscores that patent expiration does not, by itself and as a matter of law, extinguish settlement covenants—particularly where the contract’s text distinguishes patent-tethered provisions from other ongoing obligations and where “reasonableness” is fact-dependent. On remand, the parties may litigate whether the covenants indeed remained operative and whether Lilly’s conduct breached them, but that merits inquiry cannot be short-circuited at the pleading stage by imposing an unstated end date.